Jazz Wades Into Cannabinoid Weeds With $7.2bn GW Buy
Epilepsy Drug Epidiolex Adds To Sleep, Oncology Franchises
Executive Summary
Priced at a 50% premium to GW’s value, the deal will reduce the percentage of Jazz’s drug sales coming from Xyrem, provide double-digit revenue growth and expand the R&D pipeline to 19 programs.
You may also be interested in...
Acceleron To Be Next M&A Target With Rumored $11bn Deal
The Cambridge, MA-based biotech has one blockbuster-tipped drug already on the market, with another in pivotal studies.
Tech Transfer Roundup: Mydecine, Johns Hopkins Pair Up To Study Psychedelics
BioMed X teams with J&J on inflammation, drug delivery research. Stem cell firm Calidi inks licensing deals with U. of Chicago, City of Hope and Northwestern. MD Anderson teams with Blueprint and Hummingbird.
Jazz Gets Second Indication For Xywav As First Therapy For Idiopathic Hypersomnia
Following last year’s approval in cataplexy for the Xyrem follow-on, Jazz could realize additional revenue of up to $500m annually with the first and only approval in IH, analysts say.